Question-and-Answer Session
Operator
Thank you. (Operator Instruction). And our first question is from the line of Corey Tobin with William Blair & Company. Please go ahead.
Corey Tobin
Hi, good morning guys, congrats on great quarter.
Andy Eckert
Thank you Corey.
Bob Colletti
Thank you Corey.
Corey Tobin
Let me start with the clarification, Bob, on the guidance did you say 516 to 528?
Bob Colletti
Correct
Corey Tobin
Revenues for the year, okay, great.
Bob Colletti
Yes.
Corey Tobin
And the expectations for our EPSi is about 10 million for the year, is it still??
Bob Colletti
That’s right, yes. We offset our guidance, correct.
Corey Tobin
Okay, good so change there.
Bob Colletti
Correct
Corey Tobin
And then shifting gears, you start – you might hear upon this in a couple of different of the prepared marks, but, I was just curious, can you just give little bit more on the pipeline trends for three key segments, clinical systems, add ons, and revenue cycle management? And if possible I know you typically don’t give hard number but if there is any numerical or any number you could put behind it that will be helpful, thanks.
Bob Colletti
Thank you for question. Yeah, I mean, we haven’t given out specific numbers related to the pipeline, if I can just tell you that last year we had a substantial increase on our revenue cycle bookings and grew the pipeline and that progress was continued for this year. What we have been encouraged by is a resurgent from a clinical perspective as I mentioned has really accelerated based on this forthcoming payment in the events by CMS and recently four or five insurance companies that has motivated some folks to start moving on a clinical side again. So, but nevertheless revenue cycle continue to build will on the pipeline.
Corey Tobin
And with respect to EPSi, I mean, we have a very large and successful and decision support. EPSi has expanded that base obviously, and also is providing some real advantage with respect to new business decisions, new enterprise decisions where we’re able to substitute the EPSi decision in active sales records where we were selling prior to that fee occlusive VSM product that are recent prospect where it was noted as a significant advantage for us as we continue to pursue the vendor choice decision. So before you hear about the pipeline right now it remain strong and continues to build incrementally and as I mentioned earlier we are focused on building international pipeline as well.
- To read the full transcript on Seeking Alpha, click here »
